Deka Biosciences (“Deka”), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
OKC’s pro soccer club to undergo community driven brand review
Process will involve regular listening sessions and consideration of a women’s team in the future